Key takeaways
Wixela Inhub (fluticasone/salmeterol) and Cinqair (reslizumab) are both used to manage asthma, but they work in different ways and have some key differences. Wixela Inhub is an inhaled medication that combines a corticosteroid and a long-acting beta agonist to reduce inflammation and open airways. It's used for both asthma and COPD and is taken twice daily. In contrast, Cinqair is an intravenous infusion given by a healthcare provider once a month, specifically for severe asthma that isn't well-controlled by other medications. Cinqair is a monoclonal antibody that targets eosinophils, a type of white blood cell involved in inflammation. Wixela Inhub can be used in children as young as 4 years old, while Cinqair is only for adults. Additionally, Wixela Inhub has a generic version, whereas Cinqair does not. Both medications can cause serious allergic reactions, but Cinqair also carries a risk of cancerous tissue growth and parasitic infections.
